VA
EWTX icon

Verdad Advisers’s Edgewise Therapeutics EWTX Stock Holding History

Verdad Advisers’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.11M Buy
27,234
+14,182
+109% +$489K 1.06% 23
2026
Q1 		$411K Buy
+13,052
New +$376K 0.46% 77

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Verdad Advisers's EWTX Position: Q2 2026 in Review

Verdad Advisers increased its Edgewise Therapeutics (EWTX) stake by 109% in Q2 2026, buying an estimated $489K and bringing the position to 27,234 shares worth $1.11M. The position accounts for 1.06% of the portfolio, ranked #23.

Verdad Advisers first reported a position in EWTX in Q1 2026 and has held it in 2 quarters since. 225 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Verdad Advisers held 27,234 shares of Edgewise Therapeutics worth $1.11M as of Q2 2026.
  • Verdad Advisers bought 14,182 Edgewise Therapeutics shares in Q2 2026, an estimated $489K.
  • Edgewise Therapeutics made up 1.06% of Verdad Advisers's portfolio in Q2 2026, its #23 holding.
  • Verdad Advisers first reported a position in Edgewise Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 225 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Verdad Advisers's 13F filing for Q2 2026, filed 14 Aug 2026.